Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
<p>Abstract</p> <p>Background</p> <p>Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2005-02-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/5/21 |
| _version_ | 1818364293053153280 |
|---|---|
| author | Lee Jae Shin Dong Bang Soo-Mee Cho Eun Park Se Lee Young |
| author_facet | Lee Jae Shin Dong Bang Soo-Mee Cho Eun Park Se Lee Young |
| author_sort | Lee Jae |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with MBC resistant to prior anthracyclines.</p> <p>Methods</p> <p>Patients with MBC that had progressed after at least one prior chemotherapy regimen containing anthracyclines received docetaxel 75 mg/m<sup>2 </sup>followed by cisplatin 60 mg/m<sup>2 </sup>every 3 weeks for a maximum of 6 cycles or until disease progression.</p> <p>Results</p> <p>Between Jan 2000 and May 2002, 24 patients with tumors primary resistant and 15 with secondary resistant disease were accrued. All 39 patients were evaluable for safety and 36 for efficacy. The objective response rate was 31% (95% CI, 16–45%) with 3 complete responses. The median time to disease progression was 7 months, and the median overall survival was 23 months (median follow-up of 41 months). Neutropenia was the most frequently observed severe hematologic toxicity (39% of patients), whereas asthenia and nausea were the most common non-hematologic toxicities. No treatment-related death was observed.</p> <p>Conclusion</p> <p>In conclusion, we found docetaxel plus cisplatin to be an active and safe chemotherapy regimen for patients with MBC resistant to anthracyclines.</p> |
| first_indexed | 2024-12-13T22:02:04Z |
| format | Article |
| id | doaj.art-9b07615e933c49bdb80f3d66bfaa2f4e |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-13T22:02:04Z |
| publishDate | 2005-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-9b07615e933c49bdb80f3d66bfaa2f4e2022-12-21T23:29:59ZengBMCBMC Cancer1471-24072005-02-01512110.1186/1471-2407-5-21Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trialLee JaeShin DongBang Soo-MeeCho EunPark SeLee Young<p>Abstract</p> <p>Background</p> <p>Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with MBC resistant to prior anthracyclines.</p> <p>Methods</p> <p>Patients with MBC that had progressed after at least one prior chemotherapy regimen containing anthracyclines received docetaxel 75 mg/m<sup>2 </sup>followed by cisplatin 60 mg/m<sup>2 </sup>every 3 weeks for a maximum of 6 cycles or until disease progression.</p> <p>Results</p> <p>Between Jan 2000 and May 2002, 24 patients with tumors primary resistant and 15 with secondary resistant disease were accrued. All 39 patients were evaluable for safety and 36 for efficacy. The objective response rate was 31% (95% CI, 16–45%) with 3 complete responses. The median time to disease progression was 7 months, and the median overall survival was 23 months (median follow-up of 41 months). Neutropenia was the most frequently observed severe hematologic toxicity (39% of patients), whereas asthenia and nausea were the most common non-hematologic toxicities. No treatment-related death was observed.</p> <p>Conclusion</p> <p>In conclusion, we found docetaxel plus cisplatin to be an active and safe chemotherapy regimen for patients with MBC resistant to anthracyclines.</p>http://www.biomedcentral.com/1471-2407/5/21 |
| spellingShingle | Lee Jae Shin Dong Bang Soo-Mee Cho Eun Park Se Lee Young Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial BMC Cancer |
| title | Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial |
| title_full | Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial |
| title_fullStr | Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial |
| title_full_unstemmed | Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial |
| title_short | Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial |
| title_sort | docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment a phase ii clinical trial |
| url | http://www.biomedcentral.com/1471-2407/5/21 |
| work_keys_str_mv | AT leejae docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial AT shindong docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial AT bangsoomee docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial AT choeun docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial AT parkse docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial AT leeyoung docetaxelpluscisplatiniseffectiveforpatientswithmetastaticbreastcancerresistanttopreviousanthracyclinetreatmentaphaseiiclinicaltrial |